More than 500 Alzheimer’s patients in nine European countries will participate in a phase III trial designed to study the effectiveness of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota, Florida.
“We believe that Nilvadipine blocks the production of amyloid proteins linked to Alzheimer’s disease,” said Roskamp Institute President and CEO Michael Mullan, M.D., Ph.D., who along with Associate Director Fiona Crawford, Ph.D., and Daniel Paris Ph.D. led the team that developed the drug. “That means Nilvadipine is aimed at addressing the actual disease, and not just the symptoms.”
In their Sarasota laboratories, Mullan, Paris and Crawford discovered that Nilvadipine, a drug approved in Europe for treatment of hypertension, can stop the accumulation of the amyloid proteins in the brain – a development that has been implicated in Alzheimer’s disease. In 2010, the institute completed a phase I/II clinical trial in Europe that focused on Nilvadipine’s safety. “The initial results indicated that patients were able to tolerate the drug safely and appeared to benefit from treatment,” said Mullan.